HI
GANX icon

Harbour Investments’s Gain Therapeutics GANX Stock Holding History

Harbour Investments’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.8K Buy
+10,745
New +$19.8K ﹤0.01% 2905

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Harbour Investments's GANX Position: Q2 2026 in Review

Harbour Investments opened a new position in Gain Therapeutics (GANX) in Q2 2026: 10,745 shares worth $21.8K. The stake represents ﹤0.01% of the portfolio and ranks #2905 among its holdings.

50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Harbour Investments held 10,745 shares of Gain Therapeutics worth $21.8K as of Q2 2026.
  • Gain Therapeutics was a new Harbour Investments position in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #2905 holding.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.